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ABSTRACT
Background
Success in islet-transplantation-based therapies for type 1 diabetes, coupled with a
worldwide shortage of transplant-ready islets, has motivated efforts to develop renewable
sources of islet-replacement tissue. Islets and neurons share features, including common
developmental programs, and in some species brain neurons are the principal source of
systemic insulin.
Methods and Findings
Here we show that brain-derived human neural progenitor cells, exposed to a series of
signals that regulate in vivo pancreatic islet development, form clusters of glucose-responsive
insulin-producing cells (IPCs). During in vitro differentiation of neural progenitor cells with this
novel method, genes encoding essential known in vivo regulators of pancreatic islet
development were expressed. Following transplantation into immunocompromised mice, IPCs
released insulin C-peptide upon glucose challenge, remained differentiated, and did not form
detectable tumors.
Conclusion
Production of IPCs solely through extracellular factor modulation in the absence of genetic
manipulations may promote strategies to derive transplantable islet-replacement tissues from
human neural progenitor cells and other types of multipotent human stem cells.
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Advances in transplant-based therapy for type 1 diabetes
mellitus [1] and a dearth of cadaveric pancreatic islets of
Langerhans have focused interest on developing renewable
sources of transplant-ready islet-replacement tissues. Pancre-
atic islets derive from embryonic endoderm, but display
features of neurons, including a shared set of cell-autono-
mous developmental regulators [2]. Islets are the principal
source of insulin in humans, but in some invertebrate species,
such as Drosophila, brain neurons are the main source of
circulating insulin [3,4]. The similarities between islet cells
and neurons are further underscored by the demonstration
of insulin gene transcription in the vertebrate brain [5],
although it remains unclear whether these vertebrate neurons
produce or secrete insulin protein [6]. Moreover, recent
studies also suggest that in some settings, mouse pancreatic
epithelial cells can engender neuron-like cells [7,8]. These and
other ﬁndings [2] suggest that common, ancient developmen-
tal programs may govern the differentiation of islet cells and
neurons. Methods promoting neural differentiation by
embryonic stem (ES) cells have been adapted [9,10,11,12,13]
to derive insulin-producing cells (IPCs), but it remains
unclear whether such IPCs were derived from neural
progenitors, or whether a neural-based strategy can generate
transplantable human IPCs.
Neural cells derive from multipotent progenitor cells, and
recently, clonal human neural progenitor cells that remained
multipotent and karyotypically stable through at least 15
passages were puriﬁed by ﬂow-cytometry-based methods [14].
The availability of human neural progenitor cells allowed us
to investigate whether inductive signals involved in normal
pathways of islet development could direct these neural
progenitors to develop into glucose-responsive IPCs. Here we
describe experimental strategies for developing IPCs directly
from human neural stem cells.
Methods
All studies were performed in accordance with appropriate
human participants’ approval according to Stanford Univer-
sity Institutional Review Board guidelines.
Cell Lines and Culture Conditions
The human neurosphere (NS) cell lines (line numbers 1651,
1664, and 1673) were established following enrichment for
AC133
þ cells, as previously described [14], although none of
the cell lines was expanded from a single cell, and they are
therefore not clonal. The different cell lines were from
distinct donors and karyotypically normal. They gave com-
parable results, but line 1664 produced less insulin by stage 4
in our protocol than the other cell lines. Following cell thaw,
NSs were expanded in suspension culture, and in each case
were used between passages 5 and 7. Undifferentiated human
NS cells (stage 1) were cultured and expanded in medium
containing X-VIVO15 (Cambrex, Walkersville, Maryland,
United States), N2 supplement (Invitrogen, Carlsbad, Cal-
ifornia, United States), 2 lg/ml heparin, 10 ng/ml leukemia
inhibitory factor (Chemicon, Temecula, California, United
States), 20 ng/ml epidermal growth factor (R&D Systems,
Minneapolis, Minnesota, United States), and 20 ng/ml
ﬁbroblast growth factor-2 (R&D Systems), and they were
frozen after enzymatic dissociation. At stage 2, we thawed and
cultured 10
7 cells in medium made from a 1:1 mixture of
glucose-free DMEM (Invitrogen) and F-12 medium (Invitro-
gen) containing 0.2% bovine serum albumin (Sigma, St.
Louis, Missouri, United States), N2 supplement, 2 lg/ml
heparin, 10 ng/ml leukemia inhibitory factor, 20 ng/ml
epidermal growth factor, and 20 ng/ml ﬁbroblast growth
factor-2. The ﬁnal concentration of glucose in stage 2 was 5
mM. Cultures were fed weekly for up to 2 wk. Cells formed
NSs during stages 1 and 2. After 2 wk, we transferred 40–80
NSs containing a total of approximately 2–4 3 10
5 cells to
single wells in plates coated with 0.005% poly-L-ornithine
(Sigma) and 3 lg/ml ﬁbronectin (Invitrogen). These were
cultured for 2 wk (stage 3) in a 1:1 mixture of low-glucose
DMEM and F-12 media containing 100 mg/l apo-transferrin
(Sigma), 288 mg/l glucose, 73 mg/l L-glutamine, 1.69 g/l sodium
bicarbonate, 25 lg/ml bovine insulin (Sigma), 20 nM
progesterone, 100 lM putrescine, 30 nM sodium selenite,
and penicillin/streptomycin. Stage 3 medium was supple-
mented with 2 lM all-trans retinoic acid (RA) (Sigma) and had
a ﬁnal glucose concentration of either 5 or 17 mM. At stage 4,
cells were cultured in N2 medium [10] supplemented with 10
mM nicotinamide (Sigma) and 10 nM insulin-like growth
factor-1 (R&D Systems) for up to 6 d. Stage 4 medium
included 17.3 mM glucose. During stage 3 and 4, medium was
changed every other day. To examine the effect of Sonic
hedgehog (Shh) (R&D Systems), we added 300 nM mouse Shh
in PBS every other day during stage 4. To quantify neurite
outgrowths per cluster, 20 Shh-treated or control stage 4 IPC
clusters were photographed under light microscopy, and
digitized images were used to score neurites. Data are
presented as the average 6 the standard error of the mean.
Two-tailed t tests were conducted to determine statistical
signiﬁcance.
RT-PCR
Total RNA was prepared by using TRIZOL (Invitrogen) and
RQ1 RNase-free DNase (Promega, Madison, Wisconsin,
United States). For cDNA synthesis, random sequence
primers were used to prime reverse transcription reactions
and synthesis was carried out by Thermoscript RT (Invitro-
gen). A total of 35 cycles of PCR were performed using
Platinum Taq High Fidelity DNA Polymerase (Invitrogen).
GAPDH expression was used to normalize input template
cDNA to analyze relative gene expression. Primer sequences
and gene accession numbers are listed in Table 1. To conﬁrm
their identity, DNA products from PCR reactions were
excised, cloned, and sequenced.
Immunohistochemistry and Morphometry
Cell clusters were ﬁxed in 4% paraformaldehyde, embed-
ded in HistoGel (Richard-Allan Scientiﬁc, Kalamazoo, Mich-
igan, United States), and then embedded in parafﬁn. We
performed immunohistochemistry on 6-lm tissue sections.
We used primary antibodies at the following dilutions: guinea
pig anti-insulin, 1:200 (Linco Research, St. Charles, Missouri,
United States), mouse anti-b-tubulin III, 1:500 (Sigma); rabbit
anti-C-peptide, 1:100 (Linco Research); mouse anti-Nestin,
1:200 (Chemicon); mouse anti-Ki67, 1:100 (Novocastra, New-
castle, United Kingdom); rabbit anti–cleaved caspase-3, 1:200
(Cell Signaling, Beverly, Massachusetts, United States); rabbit
anti-glucagon, 1:200 (Dako, Carpinteria, California, United
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United States); mouse anti-proinsulin, 1:500 (O. Madsen,
Hagedorn, Gentofte, Denmark); mouse anti-glucokinase,
1:200 (C. Newgard, Duke University, Durham, North Carolina,
United States); mouse anti-GFAP, 1:1,000 (Dako); mouse anti-
MAP2, 1:500 (Sigma); and rabbit anti-Olig2, 1:1,000 (H.
Takebayashi, National Institute for Physiological Sciences,
Okazaki, Japan). Confocal immunoﬂuorescence microscopy
with an optical slice thickness of 0.6 lm was performed on a
Bio-Rad (Hercules, California, United States) MRC1000.
Cell counting and point-counting morphometry were
performed using standard morphometric techniques [15].
To obtain representative results, all quantiﬁcation of immu-
nostaining was performed by counting numbers of positive-
stained cells and dividing by the area of total tissues using a
standard 10 3 10 microscope grid. For quantiﬁcation of cells
expressing Nestin, Ki67, b-tubulin III, activated caspase-3,
insulin, or C-peptide, NS-derived cell clusters were ﬁxed, and
sectioned to generate 7-lm-thick tissue sections. Appropri-
ately stained cells were counted in a minimum of ten random
microscopic ﬁelds obtained from at least ten cell clusters per
condition.
In Situ Hybridization
We used human insulin cDNA (320 bp) cloned in plasmid
pCR4-TOPO (Invitrogen) as a template for in vitro tran-
scription to produce riboprobes with a digoxigenin-RNA
labeling kit (Ambion, Austin, Texas, United States), per-
formed hybridization with IPC cluster sections as described
[16], and used DIG Nucleic Acid Detection Kit (Roche,
Indianapolis, Indiana, United States) for development ac-
cording to the manufacturer’s instructions.
Insulin C-Peptide Quantification and In Vitro Insulin
Secretion Assay
At each stage, 300 NS or IPC clusters were handpicked,
washed with PBS, and homogenized; then intracellular C-
peptide content was measured with a C-peptide ELISA kit
(American Laboratory Products Company, Windham, New
Hampshire, United States). Stage 4 IPC clusters were cultured
in glucose-free RPMI (Invitrogen) supplemented with 2.8 mM
glucose, 20 mM HEPES, and 10% newborn calf serum
(Invitrogen) for at least 2–3 h. At the end of these washes,
no insulin was detectable in the wash supernatant using an
ELISA kit (American Laboratory Products Company). Fifty
IPC clusters were handpicked, transferred to a 24-well plate,
and incubated for 2 h at 37 8C in the presence of 2.8 mM
glucose, 25 mM glucose, or 25 mM sucrose. Supernatants were
then harvested for enzyme-linked immunosorption assay
(ELISA)–based quantiﬁcation of released insulin.
IPC Transplantation and Physiologic Tests
All animal studies were performed in accordance with
Stanford University Animal Care and Use Guidelines. Under
general anesthesia, 9- to 10-wk-old male NOD scid mice
(purchased from Jackson Laboratories, Bar Harbor, Maine,
United States) were engrafted with 1,000 handpicked IPC
clusters in the right and left subcapsular renal space (500 IPC
clusters each) or received a sham transplant of saline solution.
Transplantation of more IPC clusters in a renal graft site was
Table 1. Specific PCR Primers and Gene Accession Numbers
Gene Forward Primer Reverse Primer Product Size (bp) Accession Number
a
Insulin AACCAACACCTGTGCGGCTC AAGGGCTTTATTCCATCTCTCTCG 320 J00265
Nkx6.1 ACACGAGACCCACTTTTTCCG TGCTGGACTTGTGCTTCTTCAAC 348 NM_006168
ngn3 CGTGAACTCCTTGAACTGAGCAG TGGCACTCCTGGGACAGATTTC 211 AF234829
FoxA3 CATTAGGTGCTGTGCCCACTTC AGCCTTTTCTGGTTTCTCCTGG 301 NM_004497
Cdx1 GCATCTCAAGCCCCAAATGG TGATTCTGTAACCCAGTGGAGCAG 325 NM_001804
Pdx1 GGATGAAGTCTACCAAAGCTCACGC CCAGATCTTGATGTGTCTCTCGGTC 220 NM_000209
Glucokinase GAATACCCCCCAGAGACCTTTTC GGTTTCTTCCTGAGCCAGCG 182 M90299
NRSF/REST AGGTAATGGGGCAGTCTTCTGG TTCTACGACGCTGAGTTCCAAAC 350 U13879
RAR-a TCAGTGAACTCTCCACCAAGTGC TGCTTCGCAGGTCAGTAATCTTC 477 NM_000964
RAR-b GGGGCAGAGTTTGATGGAGTTG TGATTTGTCCTGGCAGACGAAG 362 BC060794
RAR-c CCACCAATAAGGAGCGACTCTTTG TTCTTCTGGATGCTTCGGCG 358 NM_000966
GAPDH TGAAGGTCGGAGTCAACGGATTTGGT CATGTGGGCCATGAGGTCCACCAC 890 NM_002046
Nestin AGAGGGGAATTCCTGGAG CTGAGGACCAGGACTCTCTA 496 NM_006617
Olig2 TCTTCCTCCTTTCTTGGCGG TCGGCAGTTTTGGGTTATTCC 342 NM_005806
En1 AAGGGACGAAACTGCGAACTCC GACACGAAAGGAAACACACTCTCG 337 NM_001426
Hb9 CCTAAGATGCCCGACTTCAACTC GCCTTTTTGCTGCGTTTCCATTTC 236 NM_005515
Isl1 AGCATCAATGTCCTCTCAACTTCC TGTTTGGCAAGGCAATGACC 493 NM_002202
Hoxc6 GGGCGGAAAAGAGGAAAAGC GGAGGGCAATCTGTAGAGTCTGAG 365 NM_004503
Hoxb9 AGGAAGCGAGGACAAAGAGAGG TTGAATACATCCCAGACAGCACTG 364 NM_024017
flk-1 TTGTGACCCAAGAATGTGTCTGTG CGAACTCTACTTTAGCCCAACTCG 492 AF035121
Brachyury CCCGCGCACTACACACCCCTCACC CCTTGGGCTGCGGCGTCGTACTG 124 AF012130
b-globin TGGACAACCTCAAGGGCACC TGGACTTAGGGAACAAAGGAACC 264 NM_000518
MLC2 AAGGCAAAGGGGTGCTGAAG AGATGGAGGTGGATAAATGGGG 310 X57542
NCAM CCTGGACTGGAATGCTGAGTATG CTCGTTGGGCTCTGTGTGTTTC 415 NM_181351
Shh GAGGTGTAAGGACAAGTTGAACGC CAGGAAAGTGAGGAAGTCGCTG 427 L38518
Ptc TTTTTCTGGGCTTGCTGGGG CGCTGTTTAGTCAACTGGCTGATG 451 U59464
Smo CTCCCCAGGTTTTCATTTAGCAC CGAGTAGACCCCCTTCTTTTGAG 409 AH007453
a National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/) accession numbers.
DOI: 10.1371/journal.pmed.0020103.t001
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after IPC cluster transplantation, we subjected mice to an
overnight fast. Then we measured serum human C-peptide
before and 30 min after intraperitoneal injection with 3 g of
glucose per kilogram of body weight using a human C-
peptide ELISA kit. When stage 4 IPC clusters were trans-
planted, tumors were not observed 4 wk after engraftment,
the maximum period of observation (n = 5). All data
represent the average (from the indicated number of samples)
6 standard error of the mean. Two-tailed t tests were
conducted to determine statistical signiﬁcance.
Results
Glucose Restriction Initiates IPC Development
Culture media with high glucose concentrations have been
useful for isolating and maintaining progenitor cell popula-
tions from the central and peripheral nervous systems [14,17]
and for permitting differentiation by neurogenic cells [18].
We routinely expanded NS cultures in medium containing 37
mM glucose, a level 5- to 6-fold higher than physiologic
glucose concentration. Isolated human neural progenitors
spontaneously aggregate in these conditions to produce a cell
cluster called a NS, and 85%–90% of NS cells produce the
intermediary ﬁlament Nestin (Figures 1 and 2), a putative
marker of neural stem and progenitor cells [19]. Prolonged
exposure to high glucose levels can also severely reduce
insulin expression in pancreatic b-cells [20]. Thus, we
postulated that glucose reduction might blunt neurogenic
programs by NSs and promote alternate fates, including
development of IPCs. Therefore, we switched NS culture
conditions from high glucose (37 mM, ‘‘stage 1’’) to low
glucose (5 mM, ‘‘stage 2’’; see Figure 1A) to initiate develop-
ment.
To assess developmental changes resulting from glucose
reduction and later culture modiﬁcations, we examined NS
cell composition, and expression of gene products known to
regulate or deﬁne in vivo fates of embryonic neural or islet
cells. A b-tubulin III isoform produced in differentiating
neurons was not detected in stage 1 cells, whereas expression
of Ki67, an S-phase-associated nuclear antigen, was expressed
in the majority of stage 1 cells (see Figure 2). Genes specifying
transcription factors essential for in vivo differentiation of
lineage-restricted neural progenitors and their differentiated
progeny [21,22,23], including En1, Hb9, Isl1, Hoxc6, NRSF/
REST, and Nkx6.1, were expressed at low or undetectable
levels in stage 1 (see Figure 1B–1C), consistent with the
reported multipotency of proliferating NSs grown in high
glucose [14].
After 2 wk at stage 2, NS-derived cells remained in clusters
(see Figure 1A), but Nestin and Ki67 were expressed in fewer
than 35% of cells (see Figure 2), indicating possible differ-
entiation of cells toward lineage-restricted fates. Consistent
with this view, we detected increased expression of Nkx6.1,
Figure 1. Development of Cells Expressing Islet Markers from Human
Neural Progenitor Cells
(A) Outline of four-stage differentiation protocol, essential factor
manipulations at each stage, and stage-speciﬁc cell cluster morphol-
ogy. Original magniﬁcation, 1003.
(B) RT-PCR analysis of gene expression by stages 1–4 cell clusters, in
stage 4 samples with RT omitted (–RT) and in human fetal spinal cord
as a control (‘‘C’’).
(C) RT-PCR analysis of expression during stages 1–4 of pancreatic
and endodermal markers. Fetal pancreas RNA served as a control
(‘‘C’’).
DOI: 10.1371/journal.pmed.0020103.g001
Figure 2. Immunohistochemical Detection of Neural Markers and Insulin
during Stages 1–4 of Human Neural Progenitor Cell Differentiation
Immunoﬂuorescent images were obtained by confocal microscopy
and are representative of at least ten samples for each antibody. We
detected insulin in only stage 4 IPCs, consistent with RT-PCR results.
Distribution of insulin staining is localized in the cytoplasm.
Immunoﬂuorescent detection of Ki67, a nuclear marker of prolifer-
ating cells, showed stage 4 IPCs are predominantly non-proliferating,
similar to mature pancreatic islets. Original magniﬁcation, 6303.
DOI: 10.1371/journal.pmed.0020103.g002
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detected increased expression of Neurogenin3 (ngn3) (see
Figure 1C), a transcription factor expressed in differentiating
neurons, and required for development of pancreatic islet
progenitor cells [24,25,26]. Nkx6.1 and ngn3 expression were
never observed in NS cultures maintained in 37 mM glucose
(see Figure 1B; data not shown). These data suggest that
glucose restriction initiates developmental programs known
to promote differentiation of mammalian neural and neuro-
endocrine cells. As shown below, insulin expression in NS-
derived cells required culture in low-glucose medium at stage
2, but we did not consistently detect insulin
þ cells by
immunohistochemistry until stage 4.
RA Promotes IPC Development
RA induces development of primitive endodermal cells
from a subset of embryonal carcinoma cell lines, and is an
endogenous signal that directs development of posterior
organs like the pancreas from embryonic endoderm [27,28].
In vivo exposure to RA is sufﬁcient to induce ectopic
development of insulin-expressing tissue in the anterior
foregut [27]. Moreover, stage 2 NS-derived cells expressed RA
receptors including RAR-a and RAR-c (see Figure 1C),
indicating competence for RA signals. To investigate whether
RA could stimulate development of NS-derived cells toward
an IPC fate, we measured expression of Pdx1, Cdx1, and FoxA3,
transcription factors that regulate gastrointestinal organ
development [29,30]. Pdx1, Cdx1, and FoxA3 expression was
induced in ‘‘stage 3,’’ when cell clusters were allowed to
adhere to pre-coated wells at a density of 40–80 NSs/cm
2 and
cultured in low-glucose medium with 2 lM RA for 2 wk (see
Figure 1A and 1C). We then tested other concentrations of
RA and other plating densities. NS cells exposed to 100 nM
RA at 20, 40, or 80 NSs/cm
2 and NS cells exposed to 2 lMR A
at a plating density of 20 NSs/cm
2 did not express these
markers or insulin at a later stage (‘‘stage 4’’; Figure 3A; data
not shown). Thus, higher doses of RA induced markers of
posterior fate in NS-derived cells, a dosage response like that
seen during RA patterning of posterior gut development in
vivo. Moreover, this response was sensitive to plating density,
revealing that additional cell-non-autonomous factors may
regulate this response. Mesoderm develops in close associa-
tion with gastrointestinal endoderm both in vivo and in vitro
[31,32]. Thus, detection of gut markers like Pdx1 and FoxA3 in
NS-derived cell cultures raised the possibility that mesoder-
mal cells might co-develop. However, we did not detect
expression of known markers of mesoderm formation,
including brachyury, ﬂk-1, myosin light chain-2, and b-globin, at
any stage in our cultures (see Figure 1B). By contrast,
mesoderm development invariably accompanies endoderm
development in embryoid bodies derived from human ES
cells or embryonic germ cells [31,32,33]. In stage 3 cultures,
Nestin and Ki67 expression was nearly extinguished (see
Figure 2), while expression of En1, ngn3, and Hb9 increased
(see Figure 1B and 1C). While their numbers increased
slightly during stage 3, b-tubulin III
þ cells composed fewer
than 10% of cells in NS-derived clusters (see Figure 2),
suggesting that the majority of differentiated cells had
acquired non-neural fates. Consistent with this interpreta-
tion, we also did not detect expression of homeodomain
proteins Hoxc6 or Hoxb9 (see Figure 1B; data not shown),
which are induced by RA in spinal cord neuronal precursor
cells [21].
RA can activate signaling through the Hedgehog (Hh)
pathway, and recent studies show that Hh signals control
Figure 3. The Sequence of Glucose Concentration Changes, Cell Density,
and Absence of Hh Signals Are Essential for Development of IPCs
(A) RT-PCR analysis of insulin gene expression for different glucose
concentrations and cell densities during stages 2–4. High glucose is
designated ‘‘H’’; low glucose designated ‘‘L.’’ Thus, maintenance of
glucose at high concentration in stages 1–4 is abbreviated as
‘‘HHHH’’; exposure to high glucose in stage 1, followed by reduction
of glucose in stages 2–4 is abbreviated ‘‘HLLL’’; and so forth. Cell
clusters analyzed here were cultured at 40–80 clusters/cm
2 except
where indicated (‘‘low density’’). Fetal pancreas RNA served as a
control (‘‘C’’).
(B) RT-PCR analysis of Hh signaling factors during stages 1–4 and in
fetal spinal cord as a control (‘‘C’’).
(C) RT-PCR analysis of stage 4 IPC expression of Shh, Desert hedgehog
(Dhh), and Indian hedgehog (Ihh). Control (‘‘C’’) is a spinal cord sample.
(D) Neurite outgrowth in control stage 4 IPC clusters, and in stage 4
IPC clusters exposed to 300 nM Shh. Original magniﬁcation, 1003.
(E) Quantiﬁcation of neurite outgrowth per control or Shh-treated
stage 4 IPC cluster. *, P , 0.001.
(F) RT-PCR analysis of IPC cluster expression of Ptc, FoxA3, Pdx1, and
insulin following treatment with Shh at stage 4. Control (‘‘C’’) is fetal
pancreas sample.
DOI: 10.1371/journal.pmed.0020103.g003
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To elucidate the mechanisms underlying RA-induced ex-
pression of markers like FoxA3 and Pdx1, we examined Hh
signaling during IPC development. We detected expression of
the Hedgehog receptors Patched (Ptc) and Smoothened (Smo) at
all stages (Figure 3B), consistent with the possibility that NS-
derived cells are competent for Hh signaling. However, we
did not detect NS expression of genes encoding Hh ligands
like Shh (Figure 3B), similar to previous studies [19]. Increased
Ptc transcription is a known consequence of Shh signaling,
but we did not detect changes of Ptc expression during stages
1–4, consistent with the absence of detectable expression of
Hh ligands. To test directly whether the absence of Hh
signaling was required for expression of endodermal or islet
markers, including FoxA3, Pdx1, and insulin, we added Shh
protein to stage 4 cultures, which do not express Shh or genes
encoding other Hh ligands like Desert hedgehog or Indian
hedgehog (Figure 3C). At 300 nM, a dose used to induce
neuronal development in ES cell cultures [21], Shh produced
a signiﬁcant increase in neurite outgrowth in NS-derived cells
(Figure 3D and 3E; see Methods), and resulted in increased Ptc
expression (Figure 3F). Moreover, Shh treatment during stage
4 eliminated expression of Pdx1, FoxA3, and insulin (Figure
3F). These data are reminiscent of prior studies demonstrat-
ing that excess endodermal Shh signaling disrupts pancreas
development in vivo [16,34]. Thus, in contrast to the response
of ES cells [21], RA treatment of NS-derived cells does not
stimulate endogenous Hh signaling. The lack of Hh signals in
NS-derived cells blunts neural differentiation and permits
differentiation toward endocrine-like cell fates.
Insulin Expression by IPCs
ngn3, Pdx1, and Hb9 are essential factors for mammalian b-
cell development [22], and their expression in stage 3
suggested the potential for deriving IPCs. Insulin expression
has not, to our knowledge, been reported in NS-derived cells
[19,35]. Moderate hyperglycemia is a potent stimulus for b-
cell differentiation and expansion in vivo and in utero [20], so
we tested whether exposure of stage 3 cells to elevated glucose
levels could induce insulin expression. Semi-quantitative RT-
PCR measures of insulin mRNA expression showed that
exposure of cultures grown in 5 mM glucose at stage 3 to 17
mM glucose at stage 4 induced insulin expression (Figure 3A).
Growth of cells at stage 2 in 5 mM glucose followed by
exposure in stages 3 and 4 to 17 mM glucose also resulted in
insulin expression at stage 4, but at lower levels. By contrast,
no insulin was expressed by cultures maintained in 5 mM
glucose or 17 mM glucose throughout stages 2–4 (Figure 3A).
Thus, reduction of glucose in stage 2 growth medium
followed by a later increase in glucose at stage 3 or 4 was
essential for development of IPCs. Insulin-like growth factor-
1 may promote insulin secretion and prevent apoptosis of b-
cells in vivo [36], and addition of this factor at stage 4 reduced
apoptosis approximately 10-fold (see Figure 1A; data not
shown). Nicotinamide, which can stimulate in vivo pancreatic
endocrine cell differentiation [37], did not affect cell survival,
but did increase insulin C-peptide expression approximately
1.5- to 2-fold (data not shown). Thus, simultaneous exposure
to high glucose levels, insulin-like growth factor-1, and
nicotinamide optimized insulin expression at stage 4. Com-
parable results were obtained with three independently
derived NS lines.
Coinciding with the onset of high insulin expression levels
in mouse islets, ngn3 expression is virtually extinguished [25],
while expression of Pdx1, FoxA3, Isl1, and Nkx6.1 in islet b-cells
is maintained or increased [22]. Similarly, we noted that IPC
maturation from stage 3 to 4 was accompanied by increased
insulin expression, reduced ngn3 expression, and increased or
maintained levels of Isl1, FoxA3, and Pdx1 expression (see
Figure 1B and 1C). Thus, tissues derived from neural
progenitor cells express insulin, Pdx1, and FoxA3, markers
typically co-expressed in foregut-derived tissues. Expression
of these markers suggests differentiation of some neural
progenitor cells toward an endoderm-like fate. We were
unable to detect expression of Pdx1 and FoxA3 using
immunohistochemical methods in stage 4 IPCs, (data not
shown). We also did not detect expression of Nkx6.1 or islet
amyloid polypeptide, markers of mature pancreatic b-cells
(see Figure 1C; data not shown). Thus, the sequence of gene
expression accompanying formation of IPCs from NSs was
similar but not identical to that described for differentiating
pancreatic b-cells, and further molecular studies are required
to determine the degree of endoderm-like differentiation of
cells in IPCs.
We detected expression of insulin protein by immunohis-
tochemistry in 90% of stage 4 cell clusters (Figure 4). An
average of 26% of cells in stage 4 clusters were insulin
þ, and
appeared healthy, with abundant cytoplasm and a well-
deﬁned nucleus delineated by the nuclear stain 7AAD (Figure
4A). Of the cells composing stage 4 clusters, 45% were b-
tubulin III
þ, none of which contained insulin (Figure 5A–5C).
Insulin
þcells showed little or no co-expression of neural stem
cell markers like Nestin (see Figure 1), or other markers of
neural lineages known to develop from human neural
progenitors, like MAP2 (differentiated neurons; Figure 5D–
5F), Olig2 (multipotent precursors, bipotent glial precursors,
and oligodendrocytes; Figure 5J–5L; see [38]), or myelin basic
protein (data not shown). Occasional rare insulin
þ cells
expressed detectable GFAP (a marker of astrocytes; Figure
5G–5I). Thus, while we cannot completely rule out the
possibility that some neural cell types expressed insulin,
these data suggest that nearly all insulin
þ cells produced in
stage 4 cultures were non-neuronal.
Nuclei in insulin
þ cells were not stained by an antibody to
Ki67 (see Figures 2 and 4B), suggesting that insulin
þ cells at
stage 4 are post-mitotic, like mature pancreatic b-cells.
Immunostaining with speciﬁc antibodies revealed proinsulin
and C-peptide, an internal portion of the proinsulin trans-
lation product, in the cytoplasm of all insulin
þ cells (see
Figure 4D–4G and 4O), supporting our conclusion that
insulin protein was produced in stage 4 IPCs. In situ
hybridization with antisense riboprobes speciﬁc for human
insulin mRNA labeled 25%–30% of stage 4 cells (see Figure
4H–4J), providing further evidence of insulin production. We
observed only rare insulin
þcells stained by antibodies speciﬁc
for activated caspase-3 (,0.3%; see Figure 4K) or TUNEL
assay (data not shown). In stage 4 cell clusters we did not
consistently detect expression of glucagon (see Figure 4L),
pancreatic polypeptide, or somatostatin by immunohisto-
chemistry. The absence of glucagon gene expression in our
IPC cultures was further conﬁrmed by RT-PCR (data not
shown). Thus, like in pancreatic islets, insulin was the
principal hormone produced by IPCs. However, the compo-
sition of IPCs was distinct from that of pancreatic islets, and
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difference.
To quantify insulin expression in IPCs, we used a human
insulin C-peptide-speciﬁc ELISA (see Figure 4P). By ELISA,
we did not detect C-peptide in stage 3 or stage 4 culture
media, which contained supplementary bovine insulin. Thus,
use of a C-peptide assay did not detect medium-derived
bovine insulin in measures of IPC insulin content [39]. C-
peptide levels at stages 1–3 were low or undetectable (see
Figure 4P), consistent with the lack of immunostainable
Figure 4. Stage 4 IPCs Express Characteristic Pancreatic b-Cell Markers and Are Glucose-Responsive
(A–C) Immunoﬂuorescent images of stage 4 IPCs were obtained by confocal microscopy and are representative of at least ten samples for each
probe. Shown is simultaneous immunoﬂuorescent staining of insulin and either the nuclear marker 7AAD (A) or Ki67 (B). (C) Lack of
immunostaining upon omission of the anti-insulin primary antibody.
(D–G) Detection of insulin C-peptide in cells stained by anti-insulin antibodies. There is complete overlap between immunostained C-peptide
and insulin in the cytoplasm.
(H and I) Representative in situ hybridization with antisense riboprobes speciﬁc for human insulin on sectioned human fetal pancreatic islet
cells (H) or a stage 4 IPC cluster (I).
(J) Sense control probe in situ hybridization on a stage 4 IPC cluster.
(K–O) Simultaneous immunoﬂuorescent detection of insulin and cleaved caspase-3 (K), glucagon (L), Glut-2 (M), glucokinase (N), or proinsulin
(O).
(P) Intracellular C-peptide content of IPCs during stages 1–4 by human C-peptide-speciﬁc ELISA.
(Q) In vitro secretion assay of stage 4 IPCs. Insulin release followed a step increase from 2.8 mM to 25 mM glucose, but not following exposure to
25 mM sucrose, which served as an osmotic control. *, p , 0.001.
(R) Serum human C-peptide detection 2-wk after sham or IPC cluster transplantation in NOD scid mice. Samples were obtained before or 30 min
after intraperitoneal glucose challenge (IPGTT).
(S) Lack of tumor growth after renal transplantation of stage 4 IPCs (graft indicated by white circle).
(T) Immunohistochemical detection of human C-peptide expression in stage 4 IPCs (cells stained brown) 2-wk after engraftment; bar is 20 lm.
Original magniﬁcation of (H–J) and (T) was 2503. All other photomicrographs’ original magniﬁcation was 6303.
DOI: 10.1371/journal.pmed.0020103.g004
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in cultures maintained in 17 mM glucose during stages 1–4
(‘‘HHHH’’), C-peptide levels were not detectable (see Figure
4P). In cell clusters exposed to 5 mM glucose in stages 2–3
then switched to 17 mM glucose at stage 4 (‘‘HLLH’’), insulin
C-peptide levels were 0.36 fmol per cluster, and the average
number of C-peptide
þ cells per cluster was 200. Thus, we
estimate 0.0018 fmol C-peptide per NS-derived IPC. A single
b-cell contains approximately 0.6 fmol C-peptide and insulin
[40], so we calculate that insulin C-peptide content in one
stage 4 IPC is approximately 0.3% of the level in isolated
human b-cells. Collectively, these experiments conﬁrm that
IPCs transcribe and translate insulin, and rule out that insulin
measured in IPCs is derived from medium, as shown in
another system [39].
IPCs Are Glucose Responsive
G l u c o k i n a s ea n dg l u c o s et r a n s p o r t e r sl i k eG l u t - 2a r e
essential regulators of glucose responses in pancreatic b-cells,
and expression of these regulators in stage 4 insulin
þcells (see
Figures 1C, 4M, and 4N) suggested that IPCs could sense and
respond to glucose. To test whether IPCs respond appropri-
ately to glucose stimulation, we measured insulin release in
static batch in vitro assays. We found that IPC insulin release
increased markedly following a step increase of glucose from
2.8 to 25 mM (see Figure 4Q). To examine whether IPCs are
similarly responsive to glucose stimulation in vivo, we
performed a series of IPC grafting experiments in immuno-
compromised recipient mice. Two weeks following engraft-
ment (1,000 IPC-containing clusters/mouse), recipient mice
and sham-transplanted controls were fasted overnight, and
human C-peptide levels measured. Human C-peptide was
undetectable in mouse sera prior to glucose challenge, or
following glucose challenge of sham-transplanted controls
(see Figure 4R). In contrast, 30 min after intraperitoneal
glucose challenge of IPC recipients we detected 6.1 6 1.2
pmol/l human C-peptide (p , 0.001), approximately 0.5%–
1% of serum C-peptide levels observed following engraft-
ment of 2,000 human islet equivalents in a prior study [41].
Thus, IPCs respond to glucose challenge in vivo by releasing
insulin C-peptide. Analysis of IPC graft sites 4 wk after
transplantation revealed nests of transplanted cells without
obvious tumor formation. Histologic analysis and immuno-
histochemical detection revealed that C-peptide-expressing
cells persisted in the graft site (see Figure 4S and 4T). Thus,
engrafted IPCs remained differentiated and survived up to a
month following transplantation.
Discussion
There is widespread interest in developing tissue replace-
ment strategies for treatment of human disorders like
diabetes mellitus and Parkinson disease. While much atten-
tion has been focused on the promise of ES cells for tissue
replacement, recent work suggests that neural stem cells, like
ES cells, may have an unusually broad differentiation
potential. For example, Gage and colleagues demonstrated
the conversion of mouse neural stem cells to the endothelial
lineage, indicating that plasticity is a bona ﬁde property of
cultured neural stem cells [42]. These results were also
unexpected because endothelial cells and neuronal cells
normally derive, respectively, from mesoderm and ectoderm,
distinct embryonic germ layers. Here we show that human
neural stem cells have a similarly broad differentiation
potential, and that speciﬁc in vitro culture conditions can
divert neural stem-derived cells from neural lineages toward
a fate with endocrine and endodermal characteristics.
Our study shows that application of endogenous signals
governing pancreas development to human neural progeni-
tor cells can generate glucose-responsive IPCs. Systematic
variation of the identity, concentration, and sequence of
these signals led to discovery of methods culminating in IPC
formation. However, there are limitations to our ﬁndings that
should be noted. First, our molecular analysis of differ-
entiating IPCs showed that they remain distinct from mature
pancreatic islet b-cells; in other words, the insulin
þ cells
derived by our methods are not mature b-cells. For example,
reverse transcriptase polymerase chain reaction conﬁrmed
that IPCs were enriched for a combination of gene products
that approximate those expressed in developing pancreatic
islet cells. However, the temporal sequence of expression of
some of these products, like glucokinase, Glut-2, and Pdx1
does not precisely recapitulate that observed in the embry-
Figure 5. Stage 4 IPCs Do Not Express Markers of Differentiated Neural
Cells
(A–C) Immunohistochemical detection of b-tubulin III (A) and insulin
(B) in stage 4 cells, and a merge of both images (C).
(D–F) Immunohistochemical detection of MAP2 (D) and insulin (E) in
stage 4 cells, and a merge of both images (F).
(G–I) Immunohistochemical detection of GFAP (G) and insulin (H) in
stage 4 cells, and a merge of both images (I).
(J–L) Immunohistochemical detction of Olig2 at stage 1 (J) and stage 4
(K) and merged view of Olig2
þ and insulin
þ cells at stage 4 (L).
Original magniﬁcation was 6303.
DOI: 10.1371/journal.pmed.0020103.g005
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genes typically expressed in b-cells, like Nkx6.1, was not
detected in later stage IPCs (see Figure 1). Thus, the insulin
þ
cells derived in this study are not bona ﬁde b-cells. Further
experimentation may elucidate the basis for these differ-
ences, revealing the extent of neural progenitor cell develop-
ment toward an endocrine cell fate. Recent studies suggest
that neural cells can be derived from adult pancreatic
epithelium [7,8], adding to a growing body of data demon-
strating numerous similarities in neural and pancreatic
endocrine development (reviewed in [43]). In light of these
similarities, we speculate that methods leading to the
production of b-cell factors like Nkx6.1 in stage 4 clusters
may enhance the b-cell-like qualities of neural-progenitor-
derived insulin
þ cells, and thereby permit differentiation of
tissues that more closely resemble endoderm-derived islet
cells. Second, our immunohistochemical analysis shows that
stage 4 insulin-expressing cells do not express markers like
Nestin, b-tubulin III, MAP2, or Olig2, suggesting that these
insulin
þ cells are non-neuronal, but we cannot formally rule
out the alternate possibility that our methods produced
neural cells capable of secreting insulin. Third, we have not
demonstrated fully that the stimulus–secretion coupling
apparatus in IPCs is similar to that in pancreatic islets. While
insulin release by IPCs produced here appears to be glucose-
sensitive, both in vitro and in vivo, future work should
elaborate whether IPC insulin is stored in dense-core
secretory vesicles, and whether secretogogues or secretion
potentiators other than glucose (like amino acids or
sulfonylureas) stimulate insulin release by IPCs, like in
pancreatic islets. Lastly, we have not ameliorated glucose
regulation in diabetic animal models with the human IPCs
described here. Serum levels of insulin C-peptide expression
achieved following IPC transplantation in glucose-challenged
mice were less than 1% of normal (see Figure 4). Thus, we did
not attempt IPC transplantations in overtly diabetic animals,
since prior studies suggest that insulin production at 10% of
normal (or greater) may be required to improve glucose
regulation in diabetic patients and animal models [10,41].
Additional studies to test the impact of transplanted IPCs in
animal models of diabetes therefore await production of IPCs
capable of insulin secretion at levels higher than achieved
here.
Nevertheless, compared to other methods for IPC develop-
ment from human stem cells [13,44], our methods produced
insulin at the highest levels yet achieved from an expandable,
human stem-cell-derived tissue. Multiple experimental ap-
proaches were taken to demonstrate that these IPCs tran-
scribe, translate, and secrete insulin, and to rule out the
possibility that insulin measured in IPCs derived from the
culture media. In vitro studies demonstrate that IPCs release
insulin in a glucose-responsive manner, like islets. Moreover,
IPCs transplanted into mice remained differentiated and
released circulating human insulin in a glucose-dependent
manner. Thus, for the ﬁrst time, we demonstrate moderately
efﬁcient production of glucose-responsive IPCs from an
expandable population of human stem cells. Current islet
transplantation methods require an estimated 5 3 10
8 to 10
9
b-cells per recipient [45]. From 10
6 cells at stage 2, we
produced an average of 200–400 clusters with approximately
2,000 cells per cluster; approximately 25% of these cells are
C-peptide
þ and release 0.5%–1% of C-peptide secreted by b-
cells. Based strictly on these yields, we would need to expand
IPC production approximately 10
5-fold to meet the need for
one transplantation. Undifferentiated NSs can be readily
expanded through at least a dozen passages [14], suggesting
sufﬁcient cell numbers could be generated to ‘‘scale up’’ this
protocol for transplant-based therapies.
We did not exhaust all possible factor combinations in our
study: we speculate that further method reﬁnements may
improve the efﬁciency of NS conversion into IPCs, as well as
IPC insulin synthesis and stimulus–secretion coupling, the
hallmark functions of mature b-cells. If so, then human neural
stem cells may serve as a valuable model for elucidating the
mechanisms and factors that regulate neuroendocrine cell
differentiation. For instance, addition of glucagon-like pep-
tide-1, TGF-b ligands, or other factors that potentiate b-cell
maturation, growth, and insulin secretion [46,47,48] may
improve the methods described here. Because our method is
based solely on extracellular factor modulation, in the
absence of genetic manipulations, it could serve as the basis
for developing replacement islets from a wide range of
human stem cells, including neural stem cells and ES cells.
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Patient Summary
Background The transplantation of insulin-secreting cells has proved
effective in treating severe cases of type 1 diabetes, but currently such
cells have to be collected from donors after death. The process of
isolation is very laborious and does not provide sufficient numbers of
cells to permit wider use of this transplant-based treatment. A renewable
source of these cells would be very valuable. Previous work has shown
that some nerve cells can also produce insulin.
What Did the Researchers Do? They took stem cells that had come
from human brains and treated them with a variety of different
substances, including glucose, to see if they could alter the way the cells
normally develop. They managed to manipulate the stem cells so that
they developed into more mature cells that secreted insulin, and could
respond to glucose. They put the cells into mice, and found that there,
too, they could respond to glucose by producing insulin, albeit at very
low levels.
What Do the Results Mean for Patients? These findings are a first step
towards producing a renewable source of insulin-producing cells;
however, the amount of insulin produced was quite low. In addition
much more work will need to be done to ensure the safety of the
procedure over the long term.
Where Can I Get More Information? The National Diabetes Information
Clearinghouse, part of the National Institute of Diabetes and Digestive
and Kidney Diseases has an information page on islet cell trans-
plantation: http://diabetes.niddk.nih.gov/dm/pubs/pancreaticislet/
Diabetes UK, a charity, also has information: http://www.diabetes.org.uk/
islets/
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